{"url":"https://lda.senate.gov/api/v1/filings/23ebc78c-99c7-4dea-b38e-a44baaaa03eb/","filing_uuid":"23ebc78c-99c7-4dea-b38e-a44baaaa03eb","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2019,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/23ebc78c-99c7-4dea-b38e-a44baaaa03eb/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Will Le","dt_posted":"2019-07-22T11:19:49.583000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1700 K Street, NW","registrant_address_2":"Suite 300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":55291,"url":"https://lda.senate.gov/api/v1/registrants/55291/","house_registrant_id":35132,"name":"BUCHANAN INGERSOLL & ROONEY PC","description":"law firm","address_1":"1700 K Street, NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILL LE","contact_telephone":"+1 202-452-5783","dt_updated":"2026-07-21T10:15:17.911194-04:00"},"client":{"id":159721,"url":"https://lda.senate.gov/api/v1/clients/159721/","client_id":1005736,"name":"MYADERM","general_description":"Producer of pharmacist-formulated, transdermal Cannabidiol (CBD) pain creams and topical C","client_government_entity":false,"client_self_select":null,"state":"CO","state_display":"Colorado","country":"US","country_display":"United States of America","ppb_state":"CO","ppb_state_display":"Colorado","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-04-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FDA Policy regarding CBD transdermal pain products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58343,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"P","last_name":"STRAZZELLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57701,"prefix":null,"prefix_display":null,"first_name":"TIMOTHY","nickname":null,"middle_name":null,"last_name":"COSTA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61183,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"WESTBROOK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"FDA Policy regarding CBD transdermal pain products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58343,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"P","last_name":"STRAZZELLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57701,"prefix":null,"prefix_display":null,"first_name":"TIMOTHY","nickname":null,"middle_name":null,"last_name":"COSTA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61183,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"WESTBROOK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"FDA Policy regarding CBD transdermal pain products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58343,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"P","last_name":"STRAZZELLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57701,"prefix":null,"prefix_display":null,"first_name":"TIMOTHY","nickname":null,"middle_name":null,"last_name":"COSTA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61183,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"WESTBROOK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}